drugset / Trial / NCT04270682

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

NCT04270682

Phase 3 Completed 19 enrolled Mirum Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The study is made up of two cohorts: a randomized double-blind crossover (placebo withdrawal with rescue) study among patients ≥ 16 years of age (adult cohort) and an open-label dose titration study among pediatric patients ≥1 month and \<16 years of age (pediatric cohort)

Timeline

Start
2020-01-31
Primary completion
2023-07-13
Completion
2023-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Chenodeoxycholic Acid Small molecule 250 mg

Indications

No indication recorded.